A Phase 3 interventional study of GB-0998 in Guillain-Barré Syndrome, sponsored by Japan Blood Products Organization. Completed at 1 site in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-02-04.
Sponsored by Japan Blood Products Organization · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will carry out to assess the efficacy of GB-0998 (intravenous immunoglobulin;400mg/kg/day for five days) in the treatment of the Guillain-Barré Syndrome based on the changes in Hughes Functional Grade (FG) as primary endpoint, and in addition, to assess the safety of GB-0998.
98 studies on the registry are indexed under Guillain-Barre Syndrome; 30 are open to participants now.
This study's enrollment of 21 is below the median of 50 across 44 interventional studies indexed under Guillain-Barre Syndrome.
Browse Guillain-Barre Syndrome studies →Japan Blood Products Organization is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GB-0998
Also known as: Venoglobulin-IH
Proportion of patients with more than 1 grade improvement in Hughes Functional Grade (FG)
Time frame: 4 weeks
days required for 1 grade improvement of FG
Time frame: 1,2,3,4,6,8,12 weeks
days required for 2 grade improvement of FG
Time frame: 1,2,3,4,6,8,12 weeks
changes in FG
Time frame: 1,2,3,4,6,8,12 weeks
proportion of patients with more than 1 grade improvement in the Arm Grade (AG) relative to baseline
Time frame: 4weeks
days required for 1 grade improvement of the AG
Time frame: 1,2,3,4,6,8,12 weeks
days required for 2 grade improvement of the AG
Time frame: 1,2,3,4,6,8,12 weeks
changes in AG
Time frame: 1,2,3,4,6,8,12 weeks
changes in grip strength
Time frame: 1,2,4,8,12 weeks
changes in manual muscle testing (MMT)
Time frame: 1,2,4,8,12 weeks
changes in activity of daily living (ADL)
Time frame: 1,2,4,8,12 weeks
changes in motor nerve conduction velocity
Time frame: 4,12 weeks
changes in FG on rescue treatment
Time frame: 1,2,3,4,6,8,12 weeks
The record gives a start of Aug 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GB-0998
Japan Blood Products Organization